@article{oai:yamanashi.repo.nii.ac.jp:00003053,
 author = {Tawata, Masato and Aida, Kaoru and Inoue, Masaharu and Kurihara, Akihiro and Iwase, Eiichi and Gan, Naoya and Onaya, Toshimasa},
 issue = {2},
 journal = {山梨医科大学雑誌, Yamanashi medical journal},
 month = {},
 note = {We evaluated the effects of epalrestat on subjective symptoms and vibration sensation in type 2 diabetic patients with neuropathy. The patients were administered epalrestat 150 mg/day orally in three divided doses for 3 months (treatment period), and the agent was discontinued for 3 months (washout period). Epalrestat relieved numbness in 12 of 16 patients after the treatment period, and numbness worsened in 5 of 11 patients after the washout period. Chi-square analysis revealed significant effects of epalrestat on numbness (p<0.001) and also on other symptoms (p<0.05). Vibration sensation was evaluated by measuring vibratory threshold using an SMV-5 vibrometer. The vibratory threshold significantly decreased in the upper (p<0.05) and the lower (p<0.01) extremities after the treatment period and increased in the lower extremity (p<0.05) after the washout period by paired t-test. There was no significant change in glycosylated hemoglobin as a whole during the study. These observations confirm that epalrestat relieves subjective symptoms and improves vibration sensation in type 2 diabetic patients with neuropathy without affecting glycemic control.},
 pages = {45--51},
 title = {<Original Article> The Effects of Epalrestat on Subjective Symptoms and Vibratory Threshold in Type 2 Diabetic Patients with Neuropathy},
 volume = {12},
 year = {1997}
}